GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (STU:6XP) » Definitions » Capital Expenditure

XSpray Pharma AB (STU:6XP) Capital Expenditure : €-3.70 Mil (TTM As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is XSpray Pharma AB Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

XSpray Pharma AB's cash flow for capital expenditures for the three months ended in Dec. 2024 was €-1.67 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2024 was €-3.70 Mil.

XSpray Pharma AB Capital Expenditure Historical Data

The historical data trend for XSpray Pharma AB's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XSpray Pharma AB Capital Expenditure Chart

XSpray Pharma AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.20 -9.34 -11.67 -4.84 -3.66

XSpray Pharma AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.51 -0.46 -0.77 -0.80 -1.67

XSpray Pharma AB Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XSpray Pharma AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (STU:6XP) » Definitions » Capital Expenditure
Comparable Companies
OSTO:EGTX OSTO:GENO OSTO:SANION OSTO:SYNACT OSTO:VICO OSTO:DMYD B XSAT:HAMLET B OSTO:HNSA OSTO:IBT B OSTO:BINV VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
XSPRAY:Sweden 0GHZ:UK
Address
Scheeles vag 2, Solna, SWE, SE-171 65
Website
https://www.xspraypharma.com
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.

XSpray Pharma AB Headlines

No Headlines